Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Zander

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Hematological Oncology|December 10, 2020
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in SwitzerlandA A Moccia, S Aeppli, S Güsewell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2009
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationH B Salvesen, S L Carter, M Mannelqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649Y Y Janjigian, K Shitara, J A Ajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Hematological Oncology|December 10, 2020
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in SwitzerlandA A Moccia, S Aeppli, S Güsewell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2009
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationH B Salvesen, S L Carter, M Mannelqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649Y Y Janjigian, K Shitara, J A Ajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Pageof 8